Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 1/2 2Phase 1 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 127Breast Neoplasms 127Ovarian Neoplasms 79Fallopian Tube Neoplasms 45Lung Neoplasms 42Carcinoma, Ovarian Epithelial 30Uterine Cervical Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 27Endometrial Neoplasms 25Triple Negative Breast Neoplasms 23Neoplasm Metastasis 21Neoplasms 20Esophageal Neoplasms 19Stomach Neoplasms 18Esophageal Squamous Cell Carcinoma 15Adenocarcinoma of Lung 13Carcinoma 12Brenner Tumor 11Recurrence 10Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Peritoneal Neoplasms 7Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma, Bronchiolo-Alveolar 5Adenocarcinoma 5Melanoma 4Carcinoma, Ductal, Breast 4Adenocarcinoma Of Esophagus 4

Interventions

Paclitaxel 2trastuzumab deruxtecan 1selinexor 1pembrolizumab 1Uterine Artery Embolization 1Hysterectomy 1Drug Therapy 1Doxorubicin 1Docetaxel 1Carboplatin 1Bupivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Uterine Neoplasms × Paclitaxel × Clear all
NCT07044336 2026-05-20

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

AstraZeneca

Phase 3 Recruiting
700 enrolled
Gynecologic

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

AstraZeneca

Phase 3 Recruiting
600 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡